What is the effect of fibrates in treating dyslipidemia associated with CKD?
A meta-analysis of data from 18 randomized trials involving 45,058 participants drawn from the general population (i.e., not specific to CKD) demonstrated a modest 10% RR reduction (95% CI 0 18; p 0.048) in major cardiovascular events and a 13% RR reduction in coronary events (95% CI 7 19; p o0.0001) for fibrate therapy. However, such benefits are smaller than the 20% reduction in vascular events and 10% reduction in mortality demonstrated by statins per mmol/l reduction in LDL-C.14,89,90